Guest: Joshua M. Bauml, MD <br>


  <p>Now that there are more targeted therapies available for metastatic non-small cell lung cancer, what are the best practices for evaluating our patients? Dr. Joshua Bauml elaborates on the opportunities and challenges faced when testing for oncogenic drivers in non-small cell lung cancer.</p>

Guest: Joshua M. Bauml, MD Now that there are more targeted therapies available for metastatic non-small cell lung cancer, what are the best practices for evaluating our patients? Dr. Joshua Bauml elaborates on the opportunities and challenges faced when testing for oncogenic drivers in non-small cell lung cancer.

What to Consider When Testing for Oncogenic Drivers in NSCLC

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
 Sponsored by

Medicine

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking. In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC. This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. Sponsored by

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
&nbsp;Sponsored by

Share What to Consider When Testing for Oncogenic Drivers in NSCLC

Sign up to save your podcasts

What to Consider When Testing for Oncogenic Drivers in NSCLC

What to Consider When Testing for Oncogenic Drivers in NSCLC